Studies conducted by Wang et al. [96] and Zhong et al. [97] found that a high pre-treatment serum ALB–BIL grade was independently associated with worse OS in HCC patients receiving TACE combined with molecular targeted therapy with sorafenib. The gene discussed is ALB; the disease is hepatocellular carcinoma.